Last updated on April 18, 2014 at 1:21 EDT

Seebri® Breezhaler® Receives European Commission Approval as Once-Daily Maintenance Treatment for COPD in the EU

September 30, 2012

TOKYO, October 1, 2012 /PRNewswire/ –

        - Approval triggers $10m milestone payment to Sosei
        - Seebri(R) Breezhaler(R) 44 mcg delivered dose approved for maintenance
          treatment of COPD will be available to patients and physicians in some EU markets by
        - In GLOW trials, Seebri(R)Breezhaler(R)improved lung function, reduced
          shortness of breath, reduced exacerbations, and improved quality of life up to 52
          weeks versus placebo[1],[2],[3]
        - GLOW2 study showed Seebri(R) Breezhaler(R) provided 24-hour bronchodilation
          and is superior to placebo and similar to open-label tiotropium in improving lung

Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) confirms the information
released today by Novartis that the European Commission has approved Seebri(R)
Breezhaler(R) (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg
glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance
bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive
pulmonary disease (COPD). This approval triggers a $10m milestone payment to Sosei.

The European Commission approved Seebri(R) Breezhaler(R) based on data from the
Novartis Phase III GLOW trials which demonstrated the safety and efficacy of
glycopyrronium 44 mcg and involved 1,996 COPD patients who required maintenance treatment
from around the world, with many in EU countries[1],[2],[3].

The GLOW trials showed that glycopyrronium, when compared to placebo, significantly
improved lung function over the first four hours after morning dosing and that this
benefit was sustained for 24 hours over a 52-week period[2]. Patients on glycopyrronium
demonstrated improved lung function, reduced shortness of breath, reduced exacerbations,
reduced use of rescue medication, improved quality of life and improved exercise tolerance
compared to placebo[1],[2],[3].

GLOW1 was a 26-week, randomized, double-blind, placebo-controlled study. The study
demonstrated the clinically significant superiority of glycopyrronium versus placebo for
lung function improvements at 12 weeks (primary endpoint) measured by trough FEV1

GLOW2 demonstrated a similar magnitude of effect and also showed that glycopyrronium
was similar to open-label (OL) tiotropium over 52 weeks measured by improvements in trough
FEV1 compared to placebo. In addition to demonstrating benefits in terms of lung function,
glycopyrronium exhibited a rapid onset of action within five minutes at first dose and
reduced exacerbations. Significant benefits in both breathlessness and health-related
quality of life (HRQL), as measured by the Transition Dyspnea Index (TDI) and St. George’s
Respiratory Questionnaire (SGRQ) compared to placebo, were also demonstrated. GLOW2 was a
52-week, randomized, double-blind, placebo-controlled study with OL tiotropium 18 mcg as
an active exploratory arm.[2]

The GLOW3 study showed that after glycopyrronium was administered in the morning,
patients experienced improved exercise tolerance from the first dose onward. Overall,
patients treated with glycopyrronium experienced a significant 21% improvement in exercise
endurance versus placebo at the end of the study (day 21), with a significant 10% increase
from day one (both p<0.001). In all studies, glycopyrronium was shown to have an overall
safety profile similar to placebo[3].

CEO of Sosei, Shinichi Tamura commented:

“We are delighted with the EU approval of Seebri Breezhaler which marks an important
milestone in the evolution of the Sosei business.

The latest Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
recommend long-acting muscarinic antagonists as first-line therapy for a broad range of
COPD patients with moderate to very severe symptoms. Seebri Breezhaler will provide an
important once-daily treatment option for this serious disease”.

Notes for editors

About Seebri(R) Breezhaler(R):

Seebri(R) Breezhaler(R) (glycopyrronium bromide) is a long-acting muscarinic
antagonist (LAMA) developed as a once-daily inhaled maintenance therapy for the treatment
of COPD. Glycopyrronium bromide was exclusively licensed to Novartis in April 2005 by
Sosei and its co-development partner Vectura. Phase III data from the GLOW 1, 2 and 3
studies demonstrated that glycopyrronium increased patients’ lung function over a 24-hour
period compared to placebo with a fast onset of action at first dose, and improved
exercise endurance versus placebo[1],[2],[3]. Seebri(R) also received MHLW approval as
once-daily maintenance treatment for COPD in Japan on 28 September 2012, under the brand
name Seebri(R) Inhalation Capsules 50mcg. The US filing for Seebri(R) Breezhaler(R) is
expected in 2014.

About QVA149:

QVA149 is an investigational inhaled, once-daily, fixed-dose combination of
indacaterol maleate and glycopyrronium bromide. QVA149 is being investigated for the
maintenance treatment of COPD in the Phase III IGNITE clinical trial program. IGNITE is
one of the largest international clinical trial programs in COPD comprising 10 studies in
total with more than 7,000 patients across 42 countries[4]-[16]. The first five studies
(ILLUMINATE, SHINE, BRIGHT, ENLIGHTEN, SPARK) have already completed in 2012 with three
additional studies (BLAZE, ARISE, BEACON) expected to complete by the end of the year. The
studies are designed to investigate efficacy, safety and tolerability, lung function,
exercise endurance, exacerbations, breathlessness and quality of life. Initial filings for
regulatory approval are expected in Q4 2012 for Europe and Japan. US filing is expected at
the end of 2014.

All Novartis inhaled COPD portfolio products are being developed for delivery via the
Breezhaler(R) device, a single-dose dry powder inhaler (SDDPI), which has low air flow
resistance, making it suitable for patients with airflow limitation, such as COPD
patients. The Breezhaler(R) device allows patients to hear, feel and see that they have
taken the drug correctly[4].

About COPD

COPD is a progressive disease associated mainly with tobacco smoking, air pollution or
occupational exposure, which can cause obstruction of airflow in the lungs resulting in
debilitating bouts of breathlessness. It affects an estimated 210 million people
worldwide[17]and is predicted to be the third leading cause of death by 2020[18]. Although
COPD is often thought of as a disease of the elderly, 50% of patients are estimated to be
within the ages of 50 and 65, which means that half of the COPD population are likely to
be impacted at the peak of their earning power and family responsibilities[19].

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global
reach. It practises a reduced risk business model by acquiring compounds from, and
bringing compounds into, Japan through exploitation of its unique position within global

For further information about Sosei, please visit http://www.sosei.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the
discovery, development and commercialisation of products. Various risks may cause Sosei’s
actual results to differ materially from those expressed or implied by the forward-looking
statements, including: adverse results in clinical development programmes; failure to
obtain patent protection for inventions; commercial limitations imposed by patents owned
or controlled by third parties; dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from development efforts; the
requirement for substantial funding to conduct research and development and to expand
commercialisation activities; and product initiatives by competitors. As a result of these
factors, prospective investors are cautioned not to rely on any forward-looking
statements. We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or


        1) D'Urzo A, et al. Efficacy and safety of once-daily NVA237 in patients
          with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research 2011, 12:156.
        2) Kerwin E, et al. Efficacy and safety of NVA237 versus placebo and tiotropium
          in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study. Eur Resp J.
          2012. Published on July 26, 2012 (doi:10.1183/09031936.00040712). Last accessed 12
          September 2012.
        3) Beeh K, Drollmann A, Di Scala L, Smith R. Once-daily NVA237 improves exercise
          endurance from first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct
          Pulmon Dis. 2012; 7:503-513.
        4) Onbrez(R) Breezhaler(R) (indacaterol) EU Summary of Product Characteristics.
          Available at:


          . Last Accessed 12 September 2012.
        5) ClinicalTrials.gov. A Study to Assess the Efficacy, Safety and Tolerability
          of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary
          Disease (COPD) (SHINE). NCT01202188.
          http://www.clinicaltrials.gov/ct2/show/NCT01202188?term=NCT01202188&rank=1. Last
          accessed 12 September 2012.
        6) ClinicalTrials.gov. QVA149 versus Fluticasone/Salmeterol in Patients With
          Chronic Obstructive Pulmonary Disease (COPD) (ILLUMINATE). NCT01315249
          http://www.clinicaltrials.gov/ct2/show/NCT01315249?term=NCT01315249&rank=1. Last
          accessed 12 September 2012.
        7) ClinicalTrials.gov. A Study to Assess the Long-term Safety of QVA149
          (ENLIGHTEN). NCT01120717


          Last accessed 12 September 2012
        8) ClinicalTrials.gov. Effect of QVA149 on Exercise Tolerance in Patients With
          Chronic Obstructive Pulmonary Disease (COPD) (BRIGHT). NCT01294787.
          http://www.clinicaltrials.gov/ct2/show/NCT01294787?term=NCT01294787.&rank=1. Last
          accessed 12 September 2012.
        9) ClinicalTrials.gov. Effect of QVA149 Versus NVA237 and Tiotropium on Chronic
          Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK). NCT01120691.
          http://www.clinicaltrials.gov/ct2/show/NCT01120691?term=NCT01120691.&rank=1. Last
          accessed 12 September 2012.
          10) ClinicalTrials.gov. Long Term Safety and Tolerability of QVA149 Versus
          Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
          (ARISE). NCT01285492.
          http://www.clinicaltrials.gov/ct2/show/NCT01285492?term=NCT01285492.&rank=1. Last
          accessed 12 September 2012.
          11) ClinicalTrials.gov. The Effect of QVA149 on Dyspnea in Patients With Chronic
          Obstructive Pulmonary Disease (COPD) (BLAZE). NCT01490125.
          http://www.clinicaltrials.gov/ct2/show/NCT01490125?term=NCT01490125.&rank=1. Last
          accessed 12 September 2012
          12) ClinicalTrials.gov. Comparison of Safety and Efficacy of the Combination
          Product QVA149A Against the Concurrent Administration of the Individual Components,
          QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
          (BEACON). http://www.clinicaltrials.gov/ct2/show/NCT01529632?term=BEACON&rank=6.
          Last accessed 12 September 2012.
          13) ClinicalTrials.gov. Comparison of Long-term Safety of the Combination
          Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive
          Pulmonary Disease Patients With Moderate to Severe Airflow Limitation (GLISTEN).
          http://www.clinicaltrials.gov/ct2/show/NCT01610037?term=GLISTEN&rank=1. Last
          accessed 12 September 2012.
          14) ClinicalTrials.gov. The Effect of QVA149 on Health Related Quality of Life
          in Patients With Chronic Obstructive Pulmonary Disease (COPD) (QUANTIFY).
          http://clinicaltrials.gov/ct2/show/NCT01574651?term=QUANTIFY&rank=1. Last accessed
          12 September 2012.
          15) FDA Access Data. Spiriva Medical Review Part 2, pages
          Last accessed 12 September 2012.
          16) FDA Access Data. Advair Medical Review Nov. 17, 2003, Page 133.


          Last accessed 12 September 2012.
          17) Global Alliance Against Chronic Respiratory Diseases (GARD). Global
          surveillance, prevention and control of chronic respiratory diseases: a comprehensive
          approach. Available at: http://www.who.int/gard/publications/GARD%20Book%202007.pdf
          Last accessed 12 September 2012.
          18) Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
          Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive
          Pulmonary Disease. Updated 2011.
          19) Fletcher MJ et al., COPD Uncovered: An International survey on the impact of
          chronic obstructive pulmonary disease (COPD) on a working age population. BMC Public
          Health 2011;11:612.

SOURCE Sosei Group Corporation

Source: PR Newswire